The Persistence of Antibodies in ESRD Patients 12 Months after the BNT162b2 Vaccine Booster Dose.

The Persistence of Antibodies in ESRD Patients 12 Months after the BNT162b2 Vaccine Booster Dose.

End-stage renal disease (ESRD) patients undergoing haemodialysis have been reported to have impaired humoral response after coronavirus disease 2019 vaccination. However, most studies focus on one antibody profile or one-time point only. Here, we longitudinally investigate the antibody response towa...

Full description

Bibliographic Details
Main Authors: Ummu Afeera, Zainulabid, Mohammad Hanif, Hashim, Abdullah Shamsir, Abd Mokti, Awla, Mohd Azraai, Hajar Fauzan, Ahmad, Ahmad Mahfuz, Gazali
Format: Article
Language:English
Published: UniKL Royal College of Medicine Perak 2024
Subjects:
HD28 Management. Industrial Management
R Medicine (General)
Online Access:http://umpir.ump.edu.my/id/eprint/41453/
http://umpir.ump.edu.my/id/eprint/41453/1/The%20Persistence%20of%20Antibodies%20in%20ESRD%20Patients%2012%20Months%20after%20the%20BNT162b2%20Vaccine%20Booster%20Dose.pdf

Internet

http://umpir.ump.edu.my/id/eprint/41453/
http://umpir.ump.edu.my/id/eprint/41453/1/The%20Persistence%20of%20Antibodies%20in%20ESRD%20Patients%2012%20Months%20after%20the%20BNT162b2%20Vaccine%20Booster%20Dose.pdf

Similar Items